<DOC>
	<DOCNO>NCT01708798</DOCNO>
	<brief_summary>Doxorubicin anthracyclines commonly use treat breast cancer type cancer . Unfortunately , cause heart muscle damage , result scarring , abnormal contraction relaxation , heart failure symptom . This side effect occur frequently high dos , limit total dose give cancer patient . Eplerenone oral medication prevents reverse heart damage disease state , commonly use treat heart failure . This study investigate use eplerenone protect heart harmful side effect doxorubicin . Few therapy show prevent heart damage patient receive anthracyclines . Small study suggest heart failure medication ( ACE inhibitor , beta-blockers ) may reduce incidence cardiac toxicity , eplerenone drug class ( aldosterone antagonist ) previously study . Eplerenone inhibits enzyme pathway cause scar heart , animal study suggest anthracyclines cause damage pathway . This study aim investigate whether eplerenone protects heart harmful effect doxorubicin chemotherapy . Specifically , measure effect eplerenone heart muscle relaxation . It randomly assign woman undergo chemotherapy doxorubicin one two group : one group receive eplerenone , group receive placebo ( sugar ) pill . The subject know type pill take . Heart muscle relaxation measure baseline , completion chemotherapy ( 8-12 week ) , 6 month . There also various blood test measure study subject , determine whether might certain blood test identify patient particularly high risk heart toxicity doxorubicin therapy .</brief_summary>
	<brief_title>Study Effect Eplerenone Heart Function Women Receiving Anthracycline Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Stage IIII breast cancer Scheduled undergo treatment doxorubicinbased chemotherapy regimen Able provide inform consent Use anthracycline agent doxorubicin Baseline LVEF â‰¤50 % modality ( nuclear , echo , MRI ) Atrial fibrillation flutter Mitral valve disease ( More mild mitral stenosis regurgitation , previous mitral valve replacement repair ) Inability obtain adequate echo image require analysis Hyperkalemia ( K+ &gt; 5.0 ) Glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73m2 Uncontrolled hypertension , define systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg Symptomatic hypotension systolic blood pressure &lt; 85 mmHg History hypersensitivity eplerenone spironolactone Significant hepatic disease ( e.g. , previously document positive serology viral hepatitis ) aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal Concomitant treatment spironolactone , potassiumsparing diuretic , potassium supplement , strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) ( i.e . ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) History alcohol and/or drug abuse Women either pregnant , lactate childbearing potential use acceptable method contraception Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result , judgment investigator , would make subject inappropriate entry trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diastolic heart failure</keyword>
</DOC>